New Delhi, India – 110 016

South Delhi Pharma, New Delhi, India

NINLARO (ixazomib) capsules

Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call at 9891296838 or Email query@southdelhipharma.com to discuss.

NINLARO is a prescription medicine. NINLARO is used to treat multiple myeloma.
INDICATIONS AND USAGE
NINLARO is a proteasome inhibitor indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
DOSAGE FORMS & STRENGTHS
Capsules: 4 mg, 3 mg, and 2.3 mg
Manufactured By: t Takeda Pharmaceuticals America, Inc.
Prescribing Information URL: Click Here

South Delhi Pharma can facilitate the supply of “NINLARO ® (ixazomib) capsules” to all locations in India and other part of countries after fulfilling the legal requirement (if applicable). All Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from South Delhi Pharma.

Category
Category

Disclaimer: Trademark shown are property of their respective owners and South Delhi Pharma (SDP) India does not lay any claim on them.

Get In Touch

Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.

The SDP is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:
info@southdelhipharma.com

Query Form

Description

Ixazomib (trade name Ninlaro) is a drug for the treatment of multiple myeloma, a type of white blood cell cancer, in combination with other drugs. It is taken by mouth in the form of capsules.
The drug was developed by Takeda. In the US, it is approved since November 2015, and in the EU since November 2016.

Ixazomib is used in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in adults after at least one prior therapy. There are no experiences with children and youths under 18 years of age.

Related Products

Related products